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Background: Combination analgesics are effective in acute pain, and a theoretical framework predicts efficacy for
combinations. The combination of dexketoprofen and tramadol is untested, but predicted to be highly effective.
Methods: This was a randomised, double-blind, double-dummy, parallel-group, placebo-controlled, single-dose trial
in patients with moderate or severe pain following third molar extraction. There were ten treatment arms, including
dexketoprofen trometamol (12.5 mg and 25 mg) and tramadol hydrochloride (37.5 mg and 75 mg), given as four
different fixed combinations and single components, with ibuprofen 400 mg as active control as well as a placebo
control. The study objective was to evaluate the superior analgesic efficacy and safety of each combination and
each single agent versus placebo. The primary outcome was the proportion of patients with at least 50 % max
TOTPAR over six hours.
Results: 606 patients were randomised and provided at least one post-dose assessment. All combinations were
significantly better than placebo. The highest percentage of responders (72 %) was achieved in the dexketoprofen
trometamol 25 mg plus tramadol hydrochloride 75 mg group (NNT 1.6, 95 % confidence interval 1.3 to 2.1).
Addition of tramadol to dexketoprofen resulted in greater peak pain relief and greater pain relief over the longer
term, particularly at times longer than six hours (median duration of 8.1 h). Adverse events were unremarkable.
Conclusions: Dexketoprofen trometamol 25 mg combined with tramadol hydrochloride 75 mg provided good
analgesia with rapid onset and long duration in a model of moderate to severe pain. The results of the dose
finding study are consistent with pre-trial calculations based on empirical formulae.
Trial registration: EudraCT (2010-022798-32); Clinicaltrials.gov (NCT01307020).
Keywords: Dexketoprofen; Tramadol; Combination analgesics; Postoperative pain; Third molar; Randomised
controlled trial; Dose range* Correspondence: andrew.moore@ndcn.ox.ac.uk
1Pain Research and Nuffield Division of Anaesthetics, Nuffield Department of
Clinical Neurology, University of Oxford, The Churchill, Oxford OX3 7LE, UK
Full list of author information is available at the end of the article
© 2015 Moore et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly credited.
Moore et al. The Journal of Headache and Pain  (2015) 16:60 Page 2 of 13Background
Greater efficacy from combination analgesics in acute
pain has been recognised for some time [1], albeit
originally in cancer pain. When oral analgesic drugs
are tested in standard, acute pain models [2] those
with the highest efficacy and lowest numbers-needed-
to-treat (NNT) are typically high doses of individual
analgesics or low doses of combinations of analgesics
[3]. Combinations of drugs of high efficacy include
paracetamol and codeine [4], paracetamol and oxycodone
[5], ibuprofen and codeine [6], ibuprofen and oxycodone
[7], and ibuprofen and paracetamol [8]. Even adding
caffeine can improve analgesic efficacy as a combination
with conventional analgesics [9].
The efficacy of combination analgesics has been shown
to be the sum of the efficacies of the individual analgesic
components, and was broadly true across a range of
different drug combinations, in postoperative pain and
migraine headache, and when tested in the same and
different trials [10]. This means that the efficacy of any
proposed combination can be assessed theoretically before
clinical trials are conducted.
A potential part of any combination might be a fast-
acting non-steroidal anti-inflammatory drug (NSAID)
formulation, because speed of absorption and onset
produces good and long lasting analgesia [11, 12].
Dexketoprofen is effective in acute pain at low doses
[13], and is also effective in a wide variety of pain con-
ditions [14]; dexketoprofen is the active chiral form
of ketoprofen. Tramadol is a widely used opioid of
proven efficacy in combination with paracetamol [15].
This study therefore aimed at evaluating the superior
analgesic efficacy and safety of dexketoprofen trometamol
and tramadol hydrochloride given as four different fixed
combinations and as single components in comparison to
placebo, on moderate to severe acute pain following
impacted third mandibular molar tooth extraction. It was
also intended to select the optimum dose combination(s)
to be further evaluated in the subsequent phase III pivotal
studies.
We used a formula derived empirically to estimate
the possible efficacy that might be obtained from dexketo-
profen and tramadol dosing combinations [10]. There
were limited data for dexketoprofen from a systematic
review [13] and two individual patient level analyses
of tramadol [16, 17]. Estimated NNTs for combinations
with dexketoprofen trometamol 25 mg and tramadol
hydrochloride 37.5 mg or 75 mg were 2.2 and 1.6,
respectively. Estimates for combinations with lower
dexketoprofen trometamol doses (12.5 mg) were higher
(worse) than 3 or above. There was limited confidence
in the NNT estimates for the combinations due to
uncertainty in the efficacy estimates of individual drugs
because of low numbers.Methods
The study (Sponsor Code DEX-TRA-02; EudraCT num-
ber 2010-022798-32) was registered at clinicaltrials.gov
(NCT01307020). It was performed at 16 study sites in six
European countries (Germany, Hungary, Italy, Poland,
Spain and the United Kingdom). It was conducted in
accordance with the principles of Good Clinical Practice
and the Declaration of Helsinki and was approved by
all the concerned Competent Authorities and Ethics
Committees. All participating patients provided written
informed consent. The clinical phase of the study started
on 23rd February 2011 (first patient screened) and
concluded on 14th October 2011 (last patient out).
Patients
Healthy male or female patients, aged 18 to 70 years, were
eligible for the study if they were scheduled for outpatient
surgical removal, under local anaesthesia, of one or more
third molars, at least one of which was fully or partially
impacted in mandibular bone. Criteria for randomisation
included postoperative pain of moderate to severe intensity
(Visual Analogue Scale [VAS] ≥40 mm and 4-point Verbal
Rating Scale [VRS] ≥2) within four hours after surgery.
Patients were excluded from the study in any of the
following circumstances: pregnant or breastfeeding women
or women of child-bearing potential not using adequate
contraception; known allergy to the study drugs, paraceta-
mol, acetylsalicylic acid, opioids or other NSAIDs; moderate
to severe renal, hepatic or cardiac dysfunction; history of
gastrointestinal disorders, bleeding disorders; epilepsy,
asthma, angioedema or related disorders; history of drug or
alcohol abuse; presence of any medical condition that in the
opinion of the investigator might pose a risk to the patient,
may confound study results or might impair compliance
with the study procedures. Patients who had received any
investigational drug or participated in any other clinical trial
within the previous month were also excluded. Further
exclusion criteria included significant surgical complica-
tions, overall surgery duration longer than one hour and
need for re-anaesthesia. Patients who had taken any analge-
sics less than 24 h before surgery were also excluded.
Concomitant use of alcohol, psychoactive drugs, sedatives
and any other medications or therapies that could pose a
risk to the patient or confound the study results were not
permitted within 48 h and two weeks before surgery (de-
pending on the half life of the respective medications) and
up to 24 h post-dose. Local application of ice and the intake
of caffeine were not permitted during the 24-hour post-
dose period. Patients had to be in fasting conditions from
two hours before surgery and up to three hours post-dose.
Study design
This was a multicentre, randomised, double-blind, double-
dummy, parallel-group, placebo-controlled, single-dose,
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arms (with balanced allocation ratio), including dex-
ketoprofen trometamol (12.5 mg and 25 mg) and
tramadol hydrochloride (37.5 mg and 75 mg) given
as four different fixed combinations (DKP12.5/TRAM37.5;
DKP12.5/TRAM75; DKP25/TRAM37.5; DKP25/TRAM75)
and as single components (DKP12.5; DKP25; TRAM37.5;
TRAM75). An active control (ibuprofen 400 mg, as an acid
formulation) was included in order to demonstrate the
sensitivity of the pain model, because it was significantly
superior to placebo in trials in the same indication [18–20],
and has the largest body of data for the indication [3].
The overall study duration was approximately 30 days
for each patient, including three visits to the study site:
Visit 1, for screening (within two weeks of their scheduled
surgery day); Visit 2, for dental surgery, randomisation
and treatment administration, followed by a 24-hour
post-dose pain and analgesic effect assessment period
(with the first four hours at the study site), during
which patients had to record efficacy data using an
electronic diary (eDiary); and Visit 3 (End of Study),
for final safety follow-up (10 ± 3 days after surgery day). In
addition, patients received a phone call for safety assess-
ment the day after Visit 2 (approximately 24 h post-dose).
For those patients who met the selection criteria, the
surgical procedure was performed under standardised
local anaesthesia, which was limited to local anaesthetic
block using lidocaine (2 %) with epinephrine (1:80.000)
up to a total volume of 5.4 mL per molar. After surgery,
patients reporting pain were asked to rate their pain
intensity (PI) by a VAS (0–100; with the left end labelled
“no pain” and the right end labelled “worst possible
pain”; [21, 22]) and by a 4-point VRS (0 = none, 1 =mild,
2 =moderate, 3 = severe; [21]) to assess their eligibility
for randomisation. Patients experiencing pain of moderate
to severe intensity (VAS ≥40 mm and VRS ≥ 2) within four
hours after the end of surgery were randomised and
received one single oral dose of the assigned study
treatment. After randomisation and immediately prior
to the administration of study medication, VRS-PI was
measured again and the score was recorded as baseline PI
for the efficacy analysis.
Participants were randomly assigned to one of 10
treatment groups following a blocked randomisation
procedure, with a block size of 10 and an allocation ratio
of 1:1:1:1:1:1:1:1:1:1. The randomisation process was
centralised by an Interactive Voice/Web Response
System (IVRS/IWRS) and the treatment code was
delivered for each patient according to a computer-
generated random allocated sequence (randomisation list)
prepared by a Sponsor’s third party prior to the start of
the study. Two sets were prepared, one set was used for
programming the IVRS/IWRS and the other set was
used for the labelling of the study medication. Personnelinvolved in the preparation or the handling of the ran-
domisation list were not involved in the study conduct
and statistical analysis. Double-blind conditions were
secured by the identical appearance and weight of the
eight tested study drugs as tablets as well as the placebo
tablet matching the tested study drugs. In order to keep
the active control ibuprofen blinded, there was also a
placebo tablet matching ibuprofen (each single-dose
treatment consisted of two tablets) leading to a double-
dummy design. The blind was maintained for patients and
for people responsible for the ongoing conduct of the
study (such as the management, monitors, investigators)
and those responsible for data analysis and interpret-
ation of results at the conclusion of the study, such
as biometrics personnel.
Rescue medication (RM) consisting of paracetamol 1 g
(with a maximum recommended daily dose of 4 g) was
available on request during the 24-hour post-dose period.
Patients were encouraged but not compelled to wait
for at least 60 min post-dose, to allow time for the
study medication to take effect.
Efficacy evaluation
Following treatment administration, patients were re-
quested to make multiple assessments of pain intensity
and pain relief (PAR) on the eDiary over a period of 24 h.
They also had to make an overall assessment of the study
medication (patient global evaluation, PGE) at the
end of this period. The time when RM was first used,
if applicable, was also recorded.
PI was measured on a 4-point VRS (0 = none, 1 =mild,
2 =moderate, 3 = severe; [21]) immediately prior the
administration of study medication (baseline PI) and
then at 15 min, 30 min, 45 min, 1 h, 1.5 h, 2 h, 2.5 h,
3 h, 3.5 h, 4 h, 5 h, 6 h, 8 h, 12 h and 24 h post-dose. PAR
was measured on a 5-point VRS (0 = none, 1 = slight,
2 = moderate, 3 = good, 4 = complete; [21]) at the
same pre-defined post-dose time points. PGE was
measured on a 5-point VRS (1 = poor, 2 = fair, 3 = good,
4 = very good, 5 = excellent; [21, 23]) at 24 h post-dose (or
whenever the patient used RM, if this occurred first).
When patients used RM, a final PI and PAR assessment
and the PGE were recorded immediately before the intake
and, after that, they were excluded from further efficacy
measurements. After use of RM, the baseline observation
carried forward (BOCF) method was applied [24], with PI
returning to its baseline score and PAR to zero for all
subsequent time points. If a patient prematurely withdrew
from the study, final PI and PAR assessment and the PGE
were also requested.
From the PI and PAR scores, the summed pain intensity
differences (SPID) and the total pain relief (TOTPAR)
over 4, 6, 8 and 12 h post-dose were calculated. SPID was
calculated as the time-weighted sum of the pain intensity
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calculated as the time-weighted sum of the PAR scores.
The percentages of the theoretical maximum possible
SPID (% max SPID) and of the theoretical maximum
possible TOTPAR (% max TOTPAR) were also calculated.
The primary efficacy endpoint was the percentage of
patients showing response, defined as the achievement
of at least 50 % of the maximum possible TOTPAR
(≥50 % max TOTPAR), over 6 h post-dose within the
respective treatment arm [3, 24].
Secondary efficacy endpoints included: percentage of
responders (≥50 % max TOTPAR) over 4, 8 and 12 h;
mean PI and PAR (VRS) scores over 24 h; SPID, % max
SPID, TOTPAR and % max TOTPAR over 4, 6, 8 and 12 h;
PGE at the end of the assessment period; time to first use
of RM since treatment administration and percentage of
patients using RM over 4, 6, 8, 12 and 24 h.
Safety evaluation
The safety evaluation was based on the incidence,
seriousness, intensity and causal relationship of treatment-
emergent adverse events (AEs). AEs were assessed
throughout the entire study by means of a non-leading
open question. Spontaneously reported AEs were also
recorded. Furthermore, safety was also evaluated by the
assessment of clinically significant changes post-dose
versus baseline in physical examination, vital signs
(VS; blood pressure and heart rate), 12-lead electrocardio-
gram (ECG) and laboratory safety tests (haematology,
biochemistry and urinalysis). Any patient who prema-
turely withdrew after having received study medication
was encouraged to undergo Visit 3.
Statistical analysis
For the primary efficacy variable, in order to demonstrate
the superiority of active treatment in comparison with
placebo the null hypothesis of equality between placebo
and each tested study drug (the four combinations and
the four corresponding single agents) was tested using a
Chi-square test. Multiplicity was adjusted by using the
Šidák correction [α =1-(1- α) ^ (1/k)], where k was the
number of comparisons. Considering eight comparisons, a
type I error probability = 0.00639 was used for the single
comparisons. The null hypothesis of equality between
placebo and the active control was also tested to validate
the pain model. In addition, event rates (ER), relative risk
(RR), NNT and relative risk reduction (RRR), with
their corresponding 95 % confidence intervals (CI),
were estimated in order to compare the effect size of
placebo with the effect size of each active treatment.
Secondary efficacy variables were analysed as follows:
percentage of responders over 4, 8 and 12 h were
analysed analogously to the primary efficacy variable;
mean PI and PAR (VRS) scores were analysed bymeans of descriptive statistics; quantitative variables
(TOTPAR, % max TOTPAR, SPID and % max SPID)
showing homogeneity of variance (according to Levene’s
test) were analysed by one-way analysis of variance
(ANOVA) using the Dunnett’s test for comparison between
placebo and each active treatment, with an overall signifi-
cance level of 5 % two-sided; ordinal variables (PGE) and
quantitative variables showing no homogeneity of variance
were analysed by the Wilcoxon rank-sum test for
comparison between placebo and each active treatment,
using the Hochberg correction for the adjustment for
multiple comparisons, with an overall significance level of
5 % two-sided; time to RM was analysed using the
Kaplan-Meier estimation method and treatment groups
were compared using a log-rank test, with the Hochberg
method applied for the multiplicity correction; percentage
of patients using RM were analysed analogously to the
primary efficacy variable. Safety variables were analysed by
means of descriptive statistics.
As an exploratory analysis, the primary efficacy endpoint
was reassessed using active control as comparator. The f
statistics test was used to evaluate if the effect of dexketo-
profen, tramadol and their combination was statistically
significant on the outcome. When at least one of the
three f tests was found to be statistically significant,
the Tukey method was applied to find out which
doses gave a significant difference on the outcome.
Statistical differences between NNTs were examined
using the z-test [25].
All efficacy analyses were performed on the “intention-
to-treat” (ITT) population (randomised patients who
received study medication and for whom at least one
post-dose assessment was available). The “per protocol”
(PP) population (patients of the ITT population with no
major protocol violations) was used to perform confirma-
tory analyses on the primary endpoint. Safety analyses
were performed on the “safety” population (randomised
patients who received study medication).
It was estimated that 540 evaluable patients (60 per
treatment arm) would have to be included in order to
achieve approximately 80 % power in rejecting the null
hypothesis of equality between placebo and the eight
experimental treatment arms (the four combinations
and the four corresponding single agents) regarding
the primary endpoint, on the basis of the following
assumptions [26]: response rate for placebo = 0.13; expected
RR of response in active treatment versus placebo = 3.21;
overall type I error probability of 0.05 (two-sided). Sixty
further patients were to be treated with the active control
as a reference for the effect of the eight experimental
treatment arms. It was expected that approximately 667
patients would have to be screened in order to obtain 600
randomised patients, assuming an approximate rate of
10 % screening failures.
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Of the 745 patients screened, 611 patients were ran-
domised and received the study treatment, thus con-
stituting the safety population. Efficacy analyses were
performed on the ITT population of 606 randomised
patients. The PP population of 567 patients was used
to perform confirmatory analyses on the primary end-
point. Patient assignment to the different populations
occurred before the study blind was broken. The partici-
pant flow with the numbers of participants who were
randomly assigned, received intended treatment, and
were analysed for the primary outcome is represented
in Additional file 1.
Demography and baseline characteristics of different
treatment groups were comparable. Demographic and
baseline characteristics of the ITT population are repre-
sented in Table 1. The overall mean age was 27 years
(range 18–64 years), 59 % were women, and 90 % were
white. The mean surgery time was 29 min, most patients
(90 %) had only one mandibular molar removed, and the
total number of molar extractions was one or two in
95 % of patients. Initial pain (baseline PI) was moderate
or severe in 601 patients (Table 2).
Four (0.65 %) patients, out of 611 randomised, discon-
tinued the study after randomisation, thus resulting in a
total of 607 patients completing the study. One patient
(allocated to DKP12.5/TRAM75) discontinued the
study due to “failure of eDiary”. The other three patients
(allocated respectively to DKP25/TRAM37.5, DKP25/
TRAM75 and TRAM37.5) were “lost to follow-up”. Three
of these four patients attended Visit 3.
Efficacy results
Primary endpoint
The percentage of patients with ≥ 50 % max TOTPAR
over six hours post-dose was significantly superior to pla-
cebo for all DKP/TRAM combinations and also for
DKP25 (p < 0.0001 for each comparison, except p = 0.0009
for DKP12.5/TRAM37.5), with the highest percentage
of responders achieved in the DKP25/TRAM75 group
(72 % versus 10 % in the placebo group; Fig. 1 and
Additional file 2.
Detailed ER, RR and NNT results at six hours are
presented in Additional file 3. DKP25/TRAM75 also
had the highest RR [7.2 (95 % CI: 3.3 to 15.7)] and
the lowest NNT [1.6 (95 % CI: 1.3 to 2.1)]. No other
point estimate for NNT was below 2.0 (Fig. 2). The
NNT for DKP25/TRAM75 was significantly better than
other NNT values (p < 0.05, z-test), except for DKP25/
TRAM37.5, DKP12.5/TRAM75 and DKP25.
The percentage of responders (≥50 % max TOTPAR)
was significantly superior to placebo for all DKP/TRAM
combinations and for both doses of DKP in monotherapy
(p < 0.0001) over four hours and it remained significantlysuperior for DKP25/TRAM75, DKP12.5/TRAM75, DKP25/
TRAM37.5 (p < 0.0001) and DKP25 (p = 0.0012) over eight
hours; and for DKP25/TRAM75 (p = 0.0002), DKP12.5/
TRAM75 (p = 0.0004) and DKP25/TRAM37.5 (p = 0.0028)
over 12 h. The highest percentage of responders over
four, eight and 12 h was achieved with DKP25/TRAM75
(79 %, 54 % and 38 % respectively) versus 6.5 % with
placebo. Results are represented in Additional file 4
and Additional file 5.
The active control, ibuprofen 400 mg, was statistically
superior to placebo (p < 0.0001), thus validating the pain
model. Analyses run on the PP population confirmed
the primary efficacy results.
Secondary endpoints
The time course of mean PAR and PI over the whole
24 h post-dose demonstrated rapid onset of pain relief
with dexketoprofen alone or in combination, and that
the addition of tramadol to dexketoprofen resulted both
in greater peak pain relief and greater pain relief over
the longer term, particularly at times longer than six
hours post dose (Fig. 3, and Additional file 6).
The analysis of summary efficacy measures (SPID, % max
SPID, TOTPAR and % max TOTPAR; Additional file 7,
Additional file 8, Additional file 9, Additional file 10 and
Additional file 11) showed that all DKP/TRAM com-
binations and both doses of DKP in monotherapy
were significantly superior to placebo (p < 0.01) except for
DKP12.5 over 12 h, with the best results achieved with
DKP25/TRAM75. The time course of mean SPID and
mean TOTPAR are represented in Additional file 12 and
Additional file 13.
The time to RM was significantly longer (p < 0.005) for
all active treatments (except for both doses of TRAM.HCl
in monotherapy) than for placebo, with DKP12.5/TRAM75
and DKP25/TRAM75 presenting the longest value
(median time, [95 % CI]: 8.5 h [5.9 to 13.0] and 8.1 h
[6.3 to 13.4] respectively, versus 1.4 h [1.2 to 1.8] in the
placebo group). Fig. 4 shows the proportion of patients
remedicating over time in each group, with additional
information in Additional file 14 and Additional file 15.
The percentage of patients requiring RM (Additional
file 16 and Additional file 17) over four and six hours was
significantly smaller (p < 0.00639) for DKP12.5/TRAM75,
DKP25/TRAM37.5, and DKP25/TRAM75 (also for DKP25
over four hours) than for placebo (over six hours 47 %,
40 %, and 38 % for each combination respectively versus
73 % for placebo). The difference remained significant for
DKP25/TRAM75 over eight hours (48 % versus 73 %) and
for DKP25/TRAM37.5 over 12 and 24 h (49 % versus 74 %
for both time points).
The PGE of the study medication at the end of the
assessment period is represented in Fig. 5. All treat-
ments (except TRAM37.5) were significantly superior





DKP 25 mg +
TRAM 37.5 mg




DKP 25 mg TRAM 37.5 mg TRAM 75 mg Ibuprofen Placebo Overall
n 60 62 63 61 60 60 59 59 60 62 606
Gender n (%) female 34 (56.7) 38 (61.3) 36 (57.1) 34 (55.7) 36 (60.0) 43 (71.7) 38 (64.4) 27 (45.8) 40 (66.7) 33 (53.2) 359 (59.2)
male 26 (43.3) 24 (38.7) 27 (42.9) 27 (44.3) 24 (40.0) 17 (28.3) 21 (35.6) 32 (54.2) 20 (33.3) 29 (46.8) 247 (40.8)
Ethnic origin n (%) White 56 (93.3) 57 (91.9) 56 (88.9) 59 (96.7) 54 (90.0) 51 (85.0) 56 (94.9) 52 (88.1) 49 (81.7) 57 (91.9) 547 (90.3)
Asian 2 (3.3) 2 (3.2) 5 (7.9) 2 (3.3) 5 (8.3) 6 (10.0) 3 (5.1) 2 (3.4) 5 (8.3) 2 (3.2) 34 (5.6)
Black 2 (3.3) 2 (3.2) 1 (1.6) 0 (0.0) 1 (1.7) 2 (3.3) 0 (0.0) 4 (6.8) 5 (8.3) 2 (3.2) 19 (3.1)
Other 0 (0.0) 1 (1.6) 1 (1.6) 0 (0.0) 0 (0.0) 1 (1.7) 0 (0.0) 1 (1.7) 1 (1.7) 1 (1.6) 6 (1.0)
Age (years) mean (SD) 28.7 (7.71) 27.0 (7.66) 26.3 (7.33) 27.3 (7.55) 27.0 (9.85) 27.0 (6.94) 25.5 (7.15) 27.9 (8.04) 26.7 (6.48) 26.1 (6.64) 26.9 (7.57)
range 18–52 18–53 18–64 18–52 18–63 18–48 18–55 18–58 18–44 18–54 18–64
BMI (kg/m2) mean (SD) 23.7 (3.38)a 24.1 (3.69) 23.0 (2.87) 23.2 (3.19) 23.6 (3.20) 23.6 (3.30)b 23.0 (3.19) 24.2 (3.10) 22.4 (3.06) 22.7 (2.80) 23.3 (3.21)
range 18–30 18–35 18–32 18–30 18–30 15–30 18–30 18–34 18–31 18–29 18–35
Surgery durationc mean (SD) 29:02 (14:40) 28:45 (12:58) 29:35 (17:32) 30:57 (16:39) 29:01 (12:03) 29:39 (14:45) 27:10 (11:10) 27:37 (14:01) 29:56 (13:31) 32:28 (15:23) 29:26 (14:23)
Total third molar
extractionsd n (%)
1 38 (63.3) 40 (64.5) 38 (60.3) 38 (62.3) 41 (68.3) 38 (63.3) 36 (61.0) 35 (59.3) 31 (51.7) 35 (56.5) 370 (61.1)
2 17 (28.3) 20 (32.3) 23 (36.5) 18 (29.5) 17 (28.3) 20 (33.3) 22 (37.3) 21 (35.6) 26 (43.3) 22 (35.5) 206 (34.0)
3 3 (5.0) 0 (0.0) 0 (0.0) 2 (3.3) 0 (0.0) 1 (1.7) 1 (1.7 ) 2 (3.4) 2 (3.3) 3 (4.8) 14 (2.3)
4 2 (3.3) 2 (3.2) 2 (3.2) 3 (4.9) 2 (3.3) 1 (1.7) 0 (0.0) 1 (1.7) 1 (1.7) 2 (3.2) 16 (2.6)
Lower third molar
extractions n (%)
1 54 (90.0) 55 (88.7) 56 (88.9) 53 (86.9) 55 (91.7) 53 (88.3) 56 (94.9) 52 (88.1) 53 (88.3) 57 (91.9) 544 (89.8)
2 6 (10.0) 7 (11.3) 7 (11.1) 8 (13.1) 5 (8.3) 7 (11.7) 3 (5.1) 7 (11.9) 7 (11.7) 5 (8.1) 62 (10.2)
BMI body mass index















Table 2 PI before randomization and before treatment administration (ITT population)
DKP 12.5 mg +
TRAM 37.5 mg
DKP 12.5 mg +
TRAM 75 mg
DKP 25 mg +
TRAM 37.5 mg
DKP 25 mg +
TRAM 75 mg
DKP 12.5 mg DKP 25 mg TRAM 37.5 mg TRAM 75 mg Ibuprofen Placebo Overall
n 60 62 63 61 60 60 59 59 60 62 606
PI before randomization
VAS Mean (SD) 58.28 (12.50) 57.74 (11.54) 56.25 (10.79) 57.72 (11.63) 58.33 (12:49) 57.72 (12.55) 57.10 (11:73) 56.32 (11.42) 57.33 (13:46) 60.34 (13.39) 57.72 (12.13)
VRS Moderate n (%) 48 (80.0) 53 (85.5) 48 (76.2) 48 (78.7) 45 (75.0) 47 (78.3) 56 (94.9) 47 (79.7) 51 (85.0) 46 (74.2) 489 (80.7)
Severe n (%) 12 (20.0) 9 (14.5) 15 (23.8) 13 (21.3) 15 (25.0) 13 (21.7) 3 (5.1) 12 (20.3) 9 (15.0) 16 (25.8) 117 (19.3)
PI before treatment administration (baseline PI)
VRS Mild n (%) 1 (1.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.7) 0 (0.0) 1 (1.6) 3 (0.5)
Moderate n (%) 40 (66.7) 43 (69.4) 39 (61.9) 41 (67.2) 35 (58.3) 43 (71.7) 40 (67.8) 35 (59.3) 39 (65.0) 33 (53.2) 388 (64.0)
Severe n (%) 19 (31.7) 18 (29.0) 24 (38.1) 20 (32.8) 25 (41.7) 17 (28.3) 19 (32.2) 23 (39.0) 21 (35.0) 27 (43.5) 213 (35.1)
Missing n (%) 0 (0.0) 1 (1.6) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.6) 2 (0.3)
VRS-PI measured on a 4-point VRS (0 = ‘none’ to 3 = ‘severe’). Baseline PI refers to the VRS-PI recorded immediately prior to the administration of the study medication (in contrast to VRS-PI measured before
















Fig. 1 Percentage of patients showing response (≥50 % max TOTPAR) over 6 h post-dose (Primary Endpoint). Maximum TOTPAR corresponds to
the theoretical maximum possible time-weighted sum of the PAR scores, measured on a 5-point VRS (0 = ‘none’ to 4 = ‘complete’)
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DKP25/TRAM75 group. The percentage of patients with
‘good’ to ‘excellent’ PGE response was 79 % in the DKP25/
TRAM75 group versus 11 % in the placebo group. The
percentage of patients with ‘very good’ and ‘excellent’ PGE
was 51 % in the DKP25/TRAM75 group versus 4.8 % in
the placebo group.
The analysis of dose–response relationship between the
tested study drugs and the active control showed that
DKP25/TRAM75 was the only combination that was
significantly superior to ibuprofen 400 mg (p = 0.0028).
Safety results
Of 611 patients treated, 40 (6.5 %) reported a total of
63 adverse reactions (ADRs), the most frequent beingFig. 2 NNT for ≥ 50 % max TOTPAR compared with placebo over six hours
maximum possible time-weighted sum of the PAR scores, measured on a 5
interval of NNT, with colour change as point estimate (Note that TRAM37.5vomiting (21 patients; 3.4 %), nausea (14 patients; 2.3 %),
dizziness (11 patients; 1.8 %) and somnolence (5 patients;
0.8 %) (Table 3). Apart from one case of “severe” somno-
lence in the DKP12.5/TRAM75 group (1.6 %), all ADRs
were considered “mild” (45 ADRs, 71 %) or “moderate”
(17 ADRs, 27 %) in intensity.
Only one serious adverse event (SAE) was reported in
one patient (allocated to the TRAM75 group), consisting in
dizziness of mild intensity, which required hospitalization
for monitoring and resolved spontaneously. The event was
assessed as “possibly related” to the study medication.
Dizziness is a commonly reported ADR associated to
the use of tramadol, occurring in more than 10 % of
patients, according to the authorized Summary of Product
Characteristics.post dose. Maximum TOTPAR corresponds to the theoretical
-point VRS (0 = ‘none’ to 4 = ‘complete’). Bars show 95 % confidence
was not significantly better than placebo)
Fig. 3 Time course of mean PAR scores (0–24 h). PAR measured on a 5-point VRS (0 = ‘none’ to 4 = ‘complete’)
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TRAM75 group (17 %). This incidence was higher
than reported in groups receiving tramadol 75 mg in
combination (i.e. DKP12.5/TRAM75 and DKP25/
TRAM75) for which the incidence was of 9.5 % and
12 % of patients, respectively.Fig. 4 Cumulative frequency (Kaplan-Meier estimation) of RM intake (0–24No deaths or other significant AEs occurred. No
patient discontinued because of AEs. There were no
clinically relevant changes in the VS, physical examination,
12-lead ECG or laboratory safety tests versus baseline.
Overall, all treatments were safe and well tolerated, with
all DKP/TRAM combinations presenting a safety andh)
Fig. 5 PGE at the end of the assessment period. PGE measured on a 5-point VRS (1 = ‘poor’ to 5 = ‘excellent’)
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lished for the single agents.
Discussion
The results of this trial demonstrate good results from a
combination of a rapidly-acting NSAID, dexketoprofen,
with a longer lasting opioid with additional enhance-
ment of serotonin and norepinephrine transmission [27].
The particular combination of dexketoprofen trometa-
mol 25 mg plus tramadol hydrochloride 75 mg delivered
rapid initial pain relief, low (good) NNT for at least 50 %
max TOTPAR over six hours, long duration, and a small
proportion of patients remedicating. The NNT of 1.6 and
the eight hours before 50 % of patients remedicated were
comparable to or better than most other oral treatments
for acute postoperative pain [3].
This makes DKP25/TRAM75 a good candidate for
a combination treatment in acute pain. In part, this is
because the combination unites two commonly used
drugs (dexketoprofen is the active chiral form of
ketoprofen) with known properties. This is important
because new rare but serious adverse events are less likely
than, say, with a new chemical. But efficacy, tolerability,
and safety need to be tested in more trials and more
patients, perhaps especially in multiple dose studies
that capture more information than a single dose efficacy
study can do.
Although this trial was performed to high quality
standards, and was relatively large with over 600 patients
recruited, the modest size of each group means thatextrapolation to clinical practice should not be under-
taken. However, the NNT for ibuprofen 400 mg was mea-
sured in this trial as 2.9 (95 % confidence interval 2.0 to
4.9); this is comfortably close to that of 2.5 (2.4 to 2.6)
found in a meta-analysis of over 6000 patients [20],
and that for dexketoprofen trometamol 25 mg of 2.2
(1.7 to 3.3) close to that of 3.2 (2.6 to 4.1) in another
meta-analysis [13], or 2.6 (2.0 to 3.5) in dental pain
in an analysis from clinical trial reports [14]. Information
on tramadol hydrochloride 75 mg in single dose studies is
limited and variable [16, 17], but the wide confidence
interval around the measured NNT of 6.7 (3.5 to 60)
encompasses existing estimates.
The other interesting, and perhaps important, result of
this trial was that the pre-trial estimates of efficacy of
the combinations, determined using a formula derived
from empirical data, proved to be reasonably accurate
predictors of measured efficacy. Because of limited
efficacy data for single dose dexketoprofen and tramadol
at the doses envisaged, the pre-trial estimates could
be little more than informed guesses, but they were
not inaccurate.
Conclusion
Dexketoprofen trometamol 25 mg combined with tramadol
hydrochloride 75 mg provided good all-round analgesia,
with rapid onset and long duration in a model of moderate
to severe pain. The results of the dose finding study are
consistent with pre-trial calculations based on empirical
formulae.
Table 3 ADRs - by system organ class /preferred term, by treatment group and overall
System organ class Preferred term DKP 12.5 mg +
TRAM 37.5 mg
DKP 12.5 mg +
TRAM 75 mg
DKP 25 mg +
TRAM 37.5 mg
DKP 25 mg +
TRAM 75 mg
DKP 12.5 mg DKP 25 mg TRAM 37.5 mg TRAM 75 mg Ibuprofen Placebo Overall
n = 61 n = 63 n = 63 n = 61 n = 60 n = 61 n = 59 n = 60 n = 61 n = 62 n = 611
Gastrointestinal
disorders
3 (4.9)|5 4 (6.3)|4 3 (4.8)|3 6 (9.8)|8 1 (1.7)|1 3 (4.9)|3 0 8 (13.3)|13 1 (1.6)|1 0 29 (4.7)|38
Abdominal pain
upper
0 0 0 0 0 0 0 1 (1.7)|1 0 0 1 (0.2)|1
Nausea 3 (4.9)|3 0 0 3 (4.9)|3 1 (1.7)|1 1 (1.6)|1 0 6 (10.0)|7 0 0 14 (2.3)|15




0 1 (1.6)|1 0 2 (3.3)|2 0 1 (1.6)|1 1 (1.7)|1 0 1 (1.6)|1 0 6 (1.0)|6
Chills 0 1 (1.6)|1 0 0 0 0 0 0 0 0 1 (0.2)|1
Discomfort 0 0 0 1 (1.6)|1 0 0 0 0 1 (1.6)|1 0 2 (0.3)|2
Feeling abnormal 0 0 0 1 (1.6)|1 0 0 0 0 0 0 1 (0.2)|1
Pyrexia 0 0 0 0 0 1 (1.6)|1 1 (1.7)|1 0 0 0 2 (0.3)|2
Nervous System
disorders
1 (1.6)|1 4 (6.3)|4 1 (1.6)|1 3 (4.9)|3 0 0 2 (3.4)|2 3 (5.0)|4 2 (3.3)|2 0 16 (2.6)|17
Dizziness 1 (1.6)|1 2 (3.2)|2 0 2 (3.3)|2 0 0 1 (1.7)|1 3 (5.0)|3 2 (3.3)|2 0 11 (1.8)|11
Headache 0 0 0 0 0 0 1 (1.7)|1 0 0 0 1 (0.2)|1
Somnolence 0 2 (3.2)|2 1 (1.6)|1 1 (1.6)|1 0 0 0 1 (1.7)|1 0 0 5 (0.8)|5
Psychiatric disorders 0 0 0 0 0 0 0 1 (1.7)|1 0 0 1 (0.2)|1
Nervousness 0 0 0 0 0 0 0 1 (1.7)|1 0 0 1 (0.2)|1
Vascular disorders 0 0 0 0 0 0 0 1 (1.7)|1 0 0 1 (0.2)|1
Hypotension 0 0 0 0 0 0 0 1 (1.7)|1 0 0 1 (0.2)|1
Overall 3 (4.9)|6 6 (9.5)|9 4 (6.3)|4 7 (11.5)|13 1 (1.7)|1 3 (4.9)|4 3 (5.1)|3 10 (16.7)|19 3 (4.9)|4 0 40 (6.5)|63















Moore et al. The Journal of Headache and Pain  (2015) 16:60 Page 12 of 13Additional files
Additional file 1: Study CONSORT flow diagram. Participant flow with
the numbers of participants who were randomly assigned, received
intended treatment, and were analysed for the primary outcome.
Additional file 2: Cumulative percentage of patients showing
response (≥50 % max TOTPAR) over 6 h post-dose (Primary
Endpoint). Maximum TOTPAR corresponds to the theoretical maximum
possible time-weighted sum of the PAR scores, measured on a 5-point
VRS (0 = ‘none’ to 4 = ‘complete’).
Additional file 3: Effect size on the percentage of patients showing
response (≥50 % max TOTPAR) over 6 h - Estimated ER, RR and NNT
(95 % CI).
Additional file 4: Percentage of patients showing response
(≥50 % max TOTPAR) over 4 h, 6 h (Primary Endpoint), 8 h and
12 h post-dose.
Additional file 5: Statistical Analysis of the percentage of patients
showing response (≥50 % max TOTPAR) over 4 h, 6 h (Primary
Endpoint), 8 h and 12 h post-dose.
Additional file 6: Time course of mean VRS-PI scores (0–24 h).
VRS-PI measured on a 4-point VRS (0 = ‘none’ to 3 = ‘severe’).
Additional file 7: Descriptive statistics (mean and SD) for SPID,
% max SPID, TOTPAR and % max TOTPAR over 4, 6, 8 and 12 h.
Additional file 8: Statistical Analysis of TOTPAR over 4, 6, 8 and
12 h.
Additional file 9: Statistical analysis of percentage of max TOTPAR
over 4, 6, 8 and 12 h.
Additional file 10: Statistical analysis of SPID over 4, 6, 8 and 12 h.
Additional file 11: Statistical analysis of percentage of max SPID
over 4, 6, 8 and 12 h.
Additional file 12: Time course of mean SPID (0–12 h). PI measured
on a 4-point VRS (0 = ‘none’ to 3 = ‘severe’); PID = PI t0h (baseline PI) – PI t
(PI at time point t). (TIFF 86 kb)
Additional file 13: Time course of mean TOTPAR (0–12 h). PAR
measured on a 5-point VRS (0 = ‘none’ to 4 = ‘complete’).
Additional file 14: Kaplan-Meier survival distribution of the time to
RM (0–24 h). Time to RM is defined as the time elapsed between the
treatment administration and the first RM use; the survival distribution
estimates the probability of ‘no use of RM’ at each time point.
Additional file 15: Time to RM (Kaplan-Meier estimation) over 24 h.
Additional file 16: Cumulative percentage of patients who required
RM over 4, 6, 8, 12 and 24 h.
Additional file 17: Statistical analysis of percentage of patients who
required RM over 4, 6, 8, 12 and 24 h.
Competing interests
The study was funded by Menarini Group. RAM and CGE have been paid
consultants for Menarini Group and have been members of speakers
bureaux, but received no direct funding for this work. SC, BPV, CGB, MB,
MPC, SS, AN, AC and CAM are employees of Menarini Group. The other
authors report no competing interests.
Authors’ contributions
The design of study was performed by RAM, CGE, SC, BPV, CGB, MB, MPC,
AC and CAM. The study was conducted by CGE, RF, ZTB, TD, SM, DTL, CMH,
AGG, PC, AW, DM and MPD. Data was analysed by RAM, SS, AN, SC, and BPV.
The manuscript was prepared by RAM, SC and BPV. All authors contributed
to the development of interim and final drafts, and read and approved the
final manuscript.
Acknowledgements
The authors acknowledge the contribution to the conduct of the study
from L Bazzichi (Università degli Studi di Pisa, Division of Rheumatology,
Department of Internal Medicine, Pisa, Italy), J Wiltfang (Universitätsklinikum
Schleswig-Holstein, Campus Kiel, Klinik für Mund-, Kiefer- undGesichtschirurgie, Plastische Operationen, Kiel, Germany), HR Metelmann
(Universitätsmedizin Greifswald, Klinik und Poliklinik für Mund-Kiefer-
Gesichtschirurgie / Plastische Operationen, Greifswald, Germany), R Baca
Pérez-Bryan (Universidad Complutense de Madrid, Facultad de Odontología,
Madrid, Spain), and to the study data management from A Madami (Menar-
ini Ricerche S.p.A.).
Author details
1Pain Research and Nuffield Division of Anaesthetics, Nuffield Department of
Clinical Neurology, University of Oxford, The Churchill, Oxford OX3 7LE, UK.
2Department of Oral and Maxillofacial Surgery, School of Dentistry, University
of Barcelona, Bellvitge Institute for Biomedical Research (IDIBELL), Barcelona,
Spain. 3Dr. Tóth Bagi Zoltán Fogászati Rendeloje, Budapest, Hungary. 4The
School of Dentistry, College of Medical and Dental Sciences, University of
Birmingham, Birmingham, UK. 5Centro Ricerche Cliniche, Ospedale Policlinico
G.B.Rossi, Verona, Italy. 6Hospital Universitario Virgen del Rocío,
Departamento de Estomatología, Facultad de Odontología, Universidad de
Sevilla, Sevilla, Spain. 7University Dental Hospital, Cardiff, UK. 8Department of
Maxillofacial Surgery, Hospital Médico Quirúrgico de Conxo, Santiago de
Compostela, Spain. 9School of Dentistry, University of Manchester,
Manchester, UK. 10Department of Oral Surgery, Warsaw Medical Univeristy,
Warsaw, Poland. 11Departament d’Estomatologia, Clínica Odontológica,
Universidad de Valencia, Valencia, Spain. 12Clinical Research, Laboratorios
Menarini S.A. – Menarini Group, Badalona, Spain. 13Clinical Research, Menarini
Ricerche S.p.A – Menarini Group, Florence, Italy.
Received: 29 April 2015 Accepted: 12 June 2015References
1. Moertel CG, Ahmann DL, Taylor WF, Schwartau N (1974) Relief of pain by
oral medications. A controlled evaluation of analgesic combinations.
JAMA 229(1):55–9
2. McQuay HJ, Derry S, Eccleston C, Wiffen PJ, Moore RA (2012) Evidence for
analgesic effect in acute pain - 50 years on. Pain 153(7):1364–7
3. Moore RA, Derry S, McQuay HJ, Wiffen PJ (2011) Single dose oral analgesics
for acute postoperative pain in adults. Cochrane Database Syst Rev
7(9):CD008659
4. Toms L, Derry S, Moore RA, McQuay HJ (2009) Single dose oral paracetamol
(acetaminophen) with codeine for postoperative pain in adults.
Cochrane Database Syst Rev 21(1):CD001547
5. Gaskell H, Derry S, Moore RA, McQuay HJ (2009) Single dose oral oxycodone
and oxycodone plus paracetamol (acetaminophen) for acute postoperative
pain in adults. Cochrane Database Syst Rev 8(3):CD002763
6. Derry S, Karlin SM, Moore RA (2013) Single dose oral ibuprofen plus codeine
for acute postoperative pain in adults. Cochrane Database Syst Rev
28(3):CD010107
7. Derry S, Derry CJ, Moore RA (2013) Single dose oral ibuprofen plus
oxycodone for acute postoperative pain in adults. Cochrane Database Syst
Rev 26(6):CD010289
8. Derry CJ, Derry S, Moore RA (2013) Single dose oral ibuprofen plus
paracetamol (acetaminophen) for acute postoperative pain. Cochrane
Database Syst Rev 24(6):CD010210
9. Derry CJ, Derry S, Moore RA (2012) Caffeine as an analgesic adjuvant for
acute pain in adults. Cochrane Database Syst Rev 14(3):CD009281
10. Moore RA, Derry CJ, Derry S, Straube S, McQuay HJ (2012) A conservative
method of testing whether combination analgesics produce additive or
synergistic effects using evidence from acute pain and migraine. Eur J Pain
16(4):585–91
11. Moore RA, Derry S, Straube S, Ireson-Paine J, Wiffen PJ (2014) Faster, higher,
stronger? Evidence for formulation and efficacy for ibuprofen in acute pain.
Pain 155(1):14–21
12. Moore RA, Derry S, Straube S, Ireson-Paine J, Wiffen PJ (2014) Validating
speed of onset as a key component of good analgesic response in acute
pain. Eur J Pain. 22. doi:10.1002/ejp.536.
13. Barden J, Derry S, McQuay HJ, Moore RA (2009) Single dose oral ketoprofen
and dexketoprofen for acute postoperative pain in adults. Cochrane Database
Syst Rev 7(4):CD007355
14. Moore RA, Barden J (2008) Systematic review of dexketoprofen in acute and
chronic pain. BMC Clin Pharmacol 8:11
Moore et al. The Journal of Headache and Pain  (2015) 16:60 Page 13 of 1315. Sawaddiruk P (2011) Tramadol hydrochloride/acetaminophen combination
for the relief of acute pain. Drugs Today (Barc) 47(10):763–72
16. Moore RA, McQuay HJ (1997) Single-patient data meta-analysis of 3453
postoperative patients: oral tramadol versus placebo, codeine and
combination analgesics. Pain 69(3):287–94
17. Edwards JE, McQuay HJ, Moore RA (2002) Combination analgesic efficacy:
individual patient data meta-analysis of single-dose oral tramadol plus
acetaminophen in acute postoperative pain. J Pain Symptom Manage
23(2):121–30
18. Cooper SA, Engel J, Ladov M, Precheur H, Rosenheck A, Rauch D (1982)
Analgesic efficacy of an ibuprofen-codeine combination. Pharmacotherapy
2(3):162–7
19. Mehlisch DR, Sollecito WA, Helfrick JF, Leibold DG, Markowitz R, Schow CE Jr,
Shultz R, Waite DE (1990) Multicenter clinical trial of ibuprofen and
acetaminophen in the treatment of postoperative dental pain. J Am
Dent Assoc 121(2):257–63
20. Derry C, Derry S, Moore RA, McQuay HJ (2009) Single dose oral ibuprofen
for acute postoperative pain in adults. Cochrane Database Syst Rev
8(3):CD001548
21. Barden J, Edwards JE, Mc Quay HJ, Moore RA (2004) Pain and analgesic
response after third molar extraction and other postsurgical pain.
Pain 107:86–90
22. Jamison RN, Gracely RH, Raymond SA, Levine JG, Marino B, Herrmann TJ,
Daly M, Fram D, Katz NP (2002) Comparative study of electronic vs. paper
VAS rating: a randomized, crossover trial using healthy volunteers.
Pain 99:341–7
23. Collins SL, Edwards J, Moore RA, Smith LA, Mc Quay HJ (2001) Seeking a
simple measure of analgesia for mega-trials: is a single global assessment
good enough? Pain 91:189–94
24. Moore RA, Edwards JE, McQuay HJ (2005) Acute pain: individual patient
meta-analysis shows the impact of different ways of analysing and
presenting results. Pain 116(3):322–31
25. Tramèr MR, Reynolds DJ, Moore RA, McQuay HJ (1997) Impact of covert
duplicate publication on meta-analysis: a case study. BMJ 315:635–640
26. Barden J, Edwards JE, Mc Quay HJ, Wiffen PJ, Moore RA (2004) Relative
efficacy of oral analgesics after third molar extraction. Br Dent J 197:407–11
27. Reeves RR, Burke RS (2008) Tramadol: basic pharmacology and emerging
concepts. Drugs Today (Barc) 44(11):827–36Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
